These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Phase I study of anguidine administered weekly.
    Author: Belt RJ, Haas CD, Joseph U, Goodwin W, Moore D, Hoogstraten B.
    Journal: Cancer Treat Rep; 1979; 63(11-12):1993-5. PubMed ID: 526932.
    Abstract:
    Anguidine was administered on a weekly schedule to 20 patients. Gastrointestinal and neurologic toxic effects were dose-limiting for both 4- and 8-hour infusions of anguidine. Myelosuppression was infrequent and not dose-related. Recommended starting doses for weekly anguidine are 6.0 mg/m2 for patients with normal hepatic function and 3.5 mg/m2 for patients with liver dysfunction.
    [Abstract] [Full Text] [Related] [New Search]